PKC EPSILON IS REQUIRED FOR KRAS-DRIVEN LUNG TUMORIGENESIS

Rachana Garg[1], **Mariana Cooke**[1,2], **Fernando Benavides**[3], **Martín C. Abba**[4], **Michelle Cicchini**[5], **David M. Feldser**[5], **Marcelo G. Kazanietz**[1,*]

[1]Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

[2]Department of Medicine, Einstein Medical Center Philadelphia, Philadelphia, PA 19141, USA.

[3]Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Smithville, TX 78957, USA.

[4]Centro de Investigaciones Inmunológicas Básicas y Aplicadas, Universidad Nacional de La Plata, CP1900, La Plata, Argentina.

[5]Department of Cancer Biology, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Abstract

Non-small cell lung cancer (NSCLC) is the most frequent subtype of lung cancer and remains a highly lethal malignancy and one of the leading causes of cancer deaths worldwide. Mutant KRAS is the prevailing oncogenic driver of lung adenocarcinoma, the most common histological form of NSCLC. In this study, we examined the role of PKCepsilon, an oncogenic kinase highly expressed in NSCLC and other cancers, in KRAS-driven tumorigenesis. Database analysis revealed an association between PKCepsilon expression and poor outcome in lung adenocarcinoma patients specifically harboring KRAS mutations. A PKCepsilon-deficient, conditionally activatable allele of oncogenic *Kras* (*LSL-Kras*^{G12D};PKCepsilon−/− mice) demonstrated the requirement of PKCepsilon for *Kras*-driven lung tumorigenesis in vivo, which was consistent with impaired transformed growth reported in PKCepsilon-deficient KRAS-dependent NSCLC cells. Moreover, PKCepsilon-knockout mice were found to be less susceptible to lung tumorigenesis induced by benzo[a]pyrene, a carcinogen that induces mutations in *Kras*. Mechanistic analysis using RNA-Seq revealed little overlap for PKCepsilon and KRAS in the control of genes and biological pathways relevant in NSCLC, suggesting that a permissive role of PKCepsilon in KRAS-driven lung tumorigenesis may involve non-redundant mechanisms. Our results thus highlight the relevance and potential of targeting PKCepsilon for lung cancer therapeutics.

*Correspondence and reprints requests should be addressed to: Marcelo G. Kazanietz (marcelog@upenn.edu) at the Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, 1256 Biomedical Research Building II/III, 421 Curie Blvd., Philadelphia, PA 19104-6160. Phone: (215)-898-0253.

Competing interests: The authors declare no conflict of interest.

Significance: These findings demonstrate that KRAS-mediated tumorigenesis requires PKCepsilon expression and highlight the potential for developing PKCepsilon targeted therapies for oncogenic RAS-driven malignancies.

Keywords

PKCε; KRAS; carcinogens; mice; lung cancer; adenocarcinoma

INTRODUCTION

Lung cancer is the leading cause of cancer-related deaths worldwide, accounting for 2.1 million new cases and 1.8 million deaths annually. Non-small cell lung cancer (NSCLC) is the most common form of lung cancer and constitutes ~85% of new diagnoses, with adenocarcinomas representing the predominant histological form. The disease is often detected at an advanced metastatic stage, resulting in poor patient prognosis (1). The vast majority of lung cancers are associated with long-term exposure to tobacco smoke and/or other environmental factors, such as benzo[a]pyrene (B[a]P) and other polycyclic aromatic hydrocarbons resulting from the combustion of organic matter. Most prevalent genetic alterations in lung adenocarcinomas include mutations in *KRAS* (~25%), *EGFR* (~15%), *PIK3CA*, *HER2* and *BRAF* (1–5%), *ALK* translocations (3–7%), and *MET* and *AXL* amplifications (1–5%). *KRAS* mutations, predominantly in codons 12–13, are found in approximately 1/3 of lung adenocarcinomas of smokers and have been associated with carcinogen exposure (1,2). Targeted therapy against mutant *KRAS* has thus far been exceptionally challenging, thus stressing the need to identify *KRAS* effectors as clinically actionable targets for disease management.

The protein kinase C (PKC) Ser-Thr kinases have been widely implicated in cancer progression. These kinases have been classified into "conventional/classical" Ca^{2+}-sensitive cPKCs (α, β and γ), ii) "novel" Ca^{2+}-insensitive nPKCs (δ, ε, η, and θ) and "atypical" aPKCs (ζ and ι). Only cPKCs and nPKCs are activated by diacylglycerol (DAG) and the phorbol ester tumor promoters. Individual PKC isozymes display unique and sometimes opposite functional properties, either acting as tumor promoting or tumor suppressive kinases (3,4). PKCε, an oncogenic member of the PKC family, has been widely implicated in cell survival, mitogenesis, motility and invasion. This kinase has been initially characterized as a transforming oncogene and subsequently recognized as a cancer biomarker, showing overexpression in multiple epithelial tumors, including lung cancer. Studies have shown that aberrantly expressed PKCε expression contributes to cancer initiation and progression (3,5,6). For example, prostate-specific PKCε overexpression in mice leads to prostatic preneoplastic lesions that evolve to overt invasive adenocarcinoma in conjunction with Pten loss (7). Transgenic PKCε overexpression in the mouse skin leads to the development of metastatic squamous cell carcinomas and enhances the susceptibility to UV radiation-induced skin cancer (8). The elevated PKCε levels in primary NSCLC tumors and cell lines has been linked to highly proliferative, survival and aggressive metastatic phenotypes (3,5,6,9). However, the association of PKCε expression with lung cancer oncogenic drivers or the susceptibility to carcinogenic insults remains unknown.

Here, we investigated the role of PKCε in lung cancer driven by mutant KRAS. Using a null PKCε mouse model, we were able to define the involvement of PKCε in KRas-mediated and chemically-induced lung carcinogenesis, thus outlining a permissive role for this kinase in tumor development.

MATERIALS AND METHODS

Cell culture

Authenticated lung adenocarcinoma cell lines were obtained from ATCC, and cultured in RPMI medium supplemented with 10% FBS, 2 mM glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. Cell lines are normally used for less than 10 passages, and they are tested for Mycoplasma at least once a year.

RNAi, transfections

Cells were transfected with siRNA duplexes for PKCε, KRAS or non-target control. For information about RNAi duplexes, see Supplementary Data.

Western blots

Immunoblotting was carried out as described in (10). Details about the commercial antibodies are presented in Supplementary Data.

Lung tumorigenesis studies

All animal studies were carried out in strict accordance with the University of Pennsylvania IACUC guidelines and IACUC approved protocols. *LSL-Kras^{G12D}* mice (The Jackson Laboratory) were crossed with PKCε KO mice (B6.129S4-*Prkce$^{tm1Msg/J}$*, kindly provided by Dr. Robert Messing, University of Texas at Austin) to generate the different experimental genotypes. To initiate Kras^{G12D} transgene expression, Ad-Cre (1.2×10^4 pfu) was inoculated intratracheally in 6–8-week old mice of three different genotypes (*LSL-Kras^{G12D}*;PKCε$^{+/+}$, *LSL-Kras^{G12D}*;PKCε$^{+/-}$ and *LSL-Kras^{G12D}*;PKCε$^{-/-}$). Excised lungs at 32 weeks post Ad-Cre delivery were subjected to H&E staining and histopathological analysis at the University of Pennsylvania Comparative Pathology Core. Kaplan-Meier analysis of mice survival was done for a period of 520 days post Ad-Cre delivery.

For carcinogenesis studies, PKCε KO mice (B6.129S4-*Prkce$^{tm1Msg/J}$*) introgressed into an A/J background were treated with B[a]P (1 mg/ml, *i.p.*, once/week for 4 weeks). Lesion analysis was done 20 weeks later. For speed congenic approach, see Supplementary Data.

RNA-Seq

Directional RNA-Seq library construction and sequencing was carried out at the UPenn NGS Core. To identify differentially regulated expression, we used the edgeR test (FDR<0.05, cut off: 2-fold change relative to NTC). Detailed methodological and bioinformatics analysis is presented as Supplementary Data.

Statistical analysis

ANOVA was performed using GraphPad Prism software built-in analysis tools. *p* values are indicated in the figure.

RESULTS AND DISCUSSION

PRKCE predicts poor outcome in mutant *KRAS* human lung adenocarcinoma

KRAS mutations are the most frequent oncogenic alterations reported in human lung adenocarcinoma and are often found in precancerous lesions such as atypical adenomatous hyperplasia (11). *Kras* mutations, primarily in codon 12, are also detected in spontaneous and chemically-induced mouse lung tumors (2). Since PKCε is up-regulated in human lung adenocarcinoma cell lines and tumors (3,6,9), we intended to ascertain if there exist any potential expression correlations with patient survival using publicly available datasets. For this analysis, we only selected samples with known *PRKCE* expression, *KRAS* mutational status and overall survival data, with a minimal follow-up of 10 months. Primary lung adenocarcinomas were divided into low *PRKCE* and high *PRKCE* according to their median expression levels. Kaplan-Meier analysis of the overall population revealed no significant differences between patients with low and high *PRKCE* expression (Fig. 1A, *upper left panel*). Patients were then stratified according to their *KRAS* mutational status, totaling 352 wild-type *KRAS* and 73 mutant *KRAS* cases (43% $KRAS^{G12C}$, 28% $KRAS^{G12V}$, 10% $KRAS^{G12D}$, 10% $KRAS^{G12A}$, 5% $KRAS^{G12C}$, 2% $KRAS^{G12R}$ and 2% $KRAS^{G12Y}$). Remarkably, whilst relatively similar outcomes were observed in patients with wild-type *KRAS* (Fig. 1A, *upper right panel*), striking differences depending on *PRKCE* expression were found in patients with mutant *KRAS* tumors. Indeed, mutant *KRAS* patients with high *PRKCE* expression showed significantly worse survival compared to those having low *PRKCE* expression (~40% *vs.* 90% survival at ten years after diagnosis; Fig. 1A, *lower left panel*). No differences in *PRKCE* expression were found between wild-type and mutant *KRAS* tumors (Fig. 1A, *lower right panel*). Therefore, high *PRKCE* expression is indicative of poor prognosis in mutant *KRAS* patients.

Genetic deletion of PKCε inhibits *Kras*-mediated lung tumorigenesis in mice

While PKC isozymes, including PKCε, have been mostly implicated in tumor promotion, emerging evidence suggests a potential role for this kinase in tumor initiation (3,6). To examine the involvement of PKCε in Kras-dependent formation of lung adenocarcinomas, we intercrossed a conditional mutant *Kras* mice ($LSL\text{-}Kras^{G12D}$) with PKCε KO mice (B6.129S4-$Prkce^{tm1Msg/J}$). Kras-dependent formation of lung adenocarcinomas was analyzed in 3 cohorts ($LSL\text{-}Kras^{G12D};Prkce^{+/+}$, $LSL\text{-}Kras^{G12D};Prkce^{+/-}$ and $LSL\text{-}Kras^{G12D};Prkce^{-/-}$ mice) upon Ad-Cre intratracheal instillation of adenoviral Cre (Ad-Cre), which removes the Lox-Stop-Lox (LSL) cassette and allows the expression of the oncogenic $Kras^{G12D}$ allele (Fig. 1B). $LSL\text{-}Kras^{G12D};Prkce^{+/+}$ mice displayed characteristic lesions as reported previously in *Kras* mutant mice (12), namely pulmonary adenoma and atypical adenomatous hyperplasia (46% of lesions) as well as bronchiolar/alveolar hyperplasia (54% of lesions). Remarkably, there was a significant reduction in the overall lesions in $LSL\text{-}Kras^{G12D};Prkce^{+/-}$ mice, and essentially no lesions were detected in $LSL\text{-}Kras^{G12D};Prkce^{-/-}$ mice (Figs. 1C). Thus, genetic deletion of the *Prkce* gene in mice impaired Kras-mediated

lung tumorigenesis. Kaplan-Meier analysis revealed a median survival of 284 days for control *LSL-Kras*^{G12D};*Prkce*$^{+/+}$ mice. However, loss of either one or two *Prkce* alleles significantly extended mice lifespan, with a median survival of 368 and 470 days, respectively (Fig. 1D).

PKCε is required for B[a]P-induced lung carcinogenesis

Thus far, an unresolved question is whether PKCε contributes to lung tumorigenesis induced by chemical carcinogens. To answer this, we employed a known B[a]P-induced lung tumorigenesis model. Since B6.129S4 genetic background is poorly sensitive to the action of carcinogens, we crossed the PKCε allele into the A/J background, which is highly susceptible to chemical carcinogenesis (13). Using a speed congenic procedure, a 97% A/J background was achieved for the PKCε KO mice (Fig. S1). The frequency of KRas mutations in lung tumors in A/J mice after B[a]P treatment is > 90%, and they predominantly occur in codon 12 (14).

Next, A/J PKCε$^{+/+}$, PKCε$^{+/−}$ and PKCε$^{−/−}$ mice (6–8-weeks) were treated with B[a]P (Fig. 2A) and their lungs analyzed 20 weeks post carcinogen treatment (Fig. 2B). Nearly all PKCε$^{+/+}$ mice (95%) developed lung lesions. Remarkably, the incidence of lesions was markedly diminished upon loss of one or two *Prkce* alleles. The incidence of B[a]P-induced adenomas in PKCε$^{+/+}$, PKCε$^{+/−}$ and PKCε$^{−/−}$ mice was 76%, 50% and 31%, respectively. A similar trend was observed for the incidence of hyperplastic lesions developed in the various groups (Fig. 2C). An average of 4.5 lung lesions was found in PKCε$^{+/+}$ mice, whereas the lesion multiplicity was significantly reduced in PKCε$^{+/−}$ and PKCε$^{−/−}$ mice (Fig. 2D). The observed inhibition of chemically-induced lung tumor formation even upon the loss of a single *Prkce* allele is a strong indicator that PKCε expression levels are key to determine susceptibility to the chemical carcinogen.

Silencing PKCε expression reduces features of transformation of *KRAS* mutant NSCLC cells without affecting signaling

We have previously reported that silencing PKCε causes a prominent reduction in the growth of H358 (KRAS^{G12C}) and H441 (KRAS^{G12V}) human lung adenocarcinoma cells. PKCε-depleted NSCLC cells have indeed impaired growth both in anchorage-dependent and anchorage-independent assays (15). PKCε growth dependency was also observed in H2009 cells (unpublished data). These cell lines are also addicted to *KRAS*, as determined by others (16). Studies implicated PKCs in mitogenic and survival signaling in cancer cells (3,5,6). However, whether PKCε mediates signaling events in KRAS mutant NSCLC cells remains undetermined. To our surprise, silencing PKCε in KRAS mutant H2009 cells failed to reduce phosphorylated (active) levels of Erk, Akt and STAT3, well-established downstream KRAS effectors (Fig. 3A). Likewise, the activation status of these effectors was not reduced upon treatment with either the "pan" PKC inhibitor (GF109203X) or the cPKC inhibitor Gö6976 (Fig. 3B). Rather, phospho-Akt levels were slightly elevated upon PKC inhibitors treatment. This effect is consistent with the known inhibition of Akt by PKCα (17), the only cPKC expressed in these cells (10). Therefore, regardless of the PKCε requirement for NSCLC cell growth and lung tumorigenesis, this kinase or other PKCs may

not act as a downstream effector of KRAS for key mitogenic and survival signaling pathways.

Differential control of gene expression by PKCε and KRAS in NSCLC cells

In our search for potential common mechanisms by which KRAS and PKCε regulate transformed growth in NSCLC cells, we explored global gene expression changes. While KRAS-dependent signatures have been established, including in lung cancer (18,19), studies suggested a limited involvement of PKCε in controlling gene expression compared to other PKCs (10,20). Using RNA-Seq, we carried out gene expression analysis in H2009 cells subjected to PKCε or KRAS depletion, using two different duplexes in each case. This analysis revealed 260 differentially regulated genes (148 up- and 112 down-regulated) by both KRAS siRNA duplexes, whereas relatively less effect was observed upon PKCε silencing (73 deregulated genes, 38 up- and 35 down-regulated). As expected, KRAS and PKCε levels were among the down-regulated genes, with nearly complete depletion with each siRNA duplex (Fig. 4A). Heatmaps of deregulated transcripts are shown in Figs. 4B, and a complete list of genes is presented in Table S1. The limited involvement of PKCε in gene expression agrees with our recent study in NSCLC cells and suggests that other PKCs (*i.e.* PKCα) are more prominently involved in transcriptional regulation (10). Nonetheless, a small overlap (15 genes) was found between KRAS- and PKCε-regulated genes, in all cases genes up-regulated upon specific silencing (Fig. 4C).

Using InnateDB, we carried out automated annotation and functional enrichment analysis of the differentially expressed genes. The top statistically significant bioprocesses regulated by KRAS included AP1 transcription factor targets, extracellular matrix (ECM) organization and degradation, integrin-β1 cell surface interaction, as well as Jak-STAT, ErbB and RAS signaling pathways. Despite the small number of genes affected by PKCε silencing, we identified a few statistically significant bioprocesses regulated by this kinase, including integrin cell surface/ECM interactions and VEGFR/PDGFR signaling pathways (Fig. 4D, *upper panel*; see Table S2 for complete list). A few bioprocesses were found to be commonly regulated by KRAS and PKCε, though the number of genes involved is relatively small, particularly in the case of PKCε (Fig. 4D, *lower panel*). Therefore, it is reasonable to speculate that the requirement of PKCε for KRAS-mediated growth and tumorigenesis does not mostly rely on common transcriptional genetic programs.

Final remarks

Our study reports for the first time the involvement of PKCε in KRAS-mediated lung tumorigenesis. The reduced number of Kras-driven and B[a]P-induced lung lesions in a PKCε-deficient background strongly argues for a key permissive role of this kinase in tumor initiation, and highlights a novel functional association between KRAS and PKCε that contributes to the development of lung cancer. Our study also underlines the striking different involvement of individual members of the PKC family in KRAS-driven lung tumorigenesis, with each PKC having unique (and sometimes opposite) roles in this context. Indeed, PKCα and PKCδ, the other two DAG-regulated PKCs expressed in NSCLC cells, have tumor suppressive or permissive roles in the context of KRas-driven lung tumorigenesis, respectively, thus underscoring the complex involvement of PKC isozymes in

lung cancer progression. Consistent with these findings, individual PKCs differentially regulate MAPK cascades in KRAS-mutant NSCLC cells (16,21). Unique to PKCε is its ability to control the expression of key apoptotic and survival proteins (15) as well as to modulate the activity of small Rho GTPases, which regulate adhesiveness, migration and epithelial-to-mesenchymal transition in KRAS-mutant cells (22). The aberrantly high PKCε expression in human NSCLC cells possibly channels DAG-mediated inputs to promote cell mitogenic and/or survival signaling that contributes to the transforming activity of oncogenic drivers.

Although a comprehensive mechanistic assessment of the hierarchical relationship between KRAS and PKCε has yet to be pursued, the fact that loss of PKCε does not substantially affect the activation status of KRAS signaling effectors or the expression of KRAS-regulated genes argues against PKCε acting as a KRAS downstream effector. Rather, we speculate that both KRAS and PKCε act in a coordinated manner through parallel pathways, whereby PKCε likely provides a facilitating input (*i.e.* a survival signal) for oncogenesis. The overlap in KRAS and PKCε bioprocesses, including those related to ECM, integrins and adhesion, together with the known PKCε involvement in integrin function and anoikis resistance (4,23,24), may throw light on the molecular basis of the KRAS-PKCε functional interaction.

NSCLC tumors display elevated PKCε levels (3,5,6,9). According to our dataset analysis, PKCε may represent a prognostic biomarker of poor outcome specifically in KRAS mutant lung adenocarcinoma patients. We speculate that PKCε contributes to disease development in a coordinated manner with specific genetic alterations, as recently shown for Pten-deficient prostate cancers (7), and serves as a marker for stratification of patients based on its expression. PKCε is involved in multiple steps of cancer progression, including tumor growth and metastasis (3,5–9), and therefore represents an attractive target for cancer therapy. Notably, a selective PKCε inhibitor reduces NSCLC cell growth in xenografts (15). Moreover, the reported reversion of Ras-mediated transformed phenotypes by pharmacological inhibition of PKCε (25) highlights unique opportunities for therapeutic interventions in KRAS-driven tumors. Given the relevance of KRAS oncogenic signaling in the progression of lung adenocarcinomas, digging into the intricacies of KRAS/PKCε interactions may uncover novel cross-talks between these players and help rationalize the potential for developing PKCε targeted therapies for oncogenic Ras-driven malignancies.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGEMENTS

REFERENCES

1. Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, et al. Non-small-cell lung cancer. Nat Rev Dis Primers 2015;1:15009. [PubMed: 27188576]

2. Nature Luch A. and nurture - lessons from chemical carcinogenesis. Nat Rev Cancer 2005;5:113–25. [PubMed: 15660110]

3. Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 2007;7:281–94. [PubMed: 17384583]

4. Newton AC, Brognard J. Reversing the Paradigm: Protein Kinase C as a Tumor Suppressor. Trends Pharmacol Sci 2017 38:438–447. [PubMed: 28283201]

5. Jain K, Basu A. The Multifunctional Protein Kinase C-epsilon in Cancer Development and Progression. Cancers (Basel) 2014;6:860–78. [PubMed: 24727247]

6. Bae KM, Wang H, Jiang G, Chen MG, Lu L, Xiao L. Protein kinase C epsilon is overexpressed in primary human non-small cell lung cancers and functionally required for proliferation of non-small cell lung cancer cells in a p21/Cip1-dependent manner. Cancer Res 2007;67:6053–63. [PubMed: 17616661]

7. Garg R, Blando JM, Perez CJ, Abba MC, Benavides F, Kazanietz MG. Protein Kinase C Epsilon Cooperates with PTEN Loss for Prostate Tumorigenesis through the CXCL13-CXCR5 Pathway. Cell Rep 2017;19:375–88. [PubMed: 28402859]

8. Verma AK, Wheeler DL, Aziz MH, Manoharan H. Protein kinase Cepsilon and development of squamous cell carcinoma, the nonmelanoma human skin cancer. Mol Carcinog 2006;45:381–88. [PubMed: 16683253]

9. Caino MC, Lopez-Haber C, Kissil JL, Kazanietz MG. Non-small cell lung carcinoma cell motility, rac activation and metastatic dissemination are mediated by protein kinase C epsilon. PLoS One 2012;7:e31714.

10. Cooke M, Casado-Medrano V, Ann J, Lee J, Blumberg PM, Abba MC, et al. Differential Regulation of Gene Expression in Lung Cancer Cells by Diacyglycerol-Lactones and a Phorbol Ester Via Selective Activation of Protein Kinase C Isozymes. Sci Rep 2019;9:6041. [PubMed: 30988374]

11. Cooper CA, Carby FA, Bubb VJ, Lamb D, Kerr KM, Wyllie AH. The pattern of K-ras mutation in pulmonary adenocarcinoma defines a new pathway of tumour development in the human lung. J Pathol 1997;181:401–4. [PubMed: 9196437]

12. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001;15:3243–8. [PubMed: 11751630]

13. Malkinson AM. The genetic basis of susceptibility to lung tumors in mice. Toxicology 1989;54:241–71. [PubMed: 2650016]

14. You M, Candrian U, Maronpot RR, Stoner GD, Anderson MW. Activation of the Ki-ras protooncogene in spontaneously occurring and chemically induced lung tumors of the strain A mouse. Proc Natl Acad Sci USA 1989;86:3070–4. [PubMed: 2654935]

15. Caino MC, Lopez-Haber C, Kim J, Mochly-Rosen D, Kazanietz MG. Protein kinase Cε is required for non-small cell lung carcinoma growth and regulates the expression of apoptotic genes. Oncogene 2012;31:2593–600. [PubMed: 21996750]

16. Ohm AM, Tan AC, Heasley LE, Reyland ME. Co-dependency of PKCdelta and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer. Oncogene 2017;36:4370–8. [PubMed: 28368426]

17. Tanaka Y, Gavrielides MV, Mitsuuchi Y, Fujii T, Kazanietz MG. Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the Akt survival pathway. J Biol Chem 2003;278:33753–62. [PubMed: 12824193]

18. Sweet-Cordero A, Mukherjee S, Subramanian A, You H, Roix JJ, Ladd-Acosta C, et al. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet 2005;37:48–55. [PubMed: 15608639]

19. Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N, et al. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 2009;15:489–500. [PubMed: 19477428]

20. Caino MC, von Burstin VA, Lopez-Haber C, Kazanietz MG. Differential regulation of gene expression by protein kinase C isozymes as determined by genome-wide expression analysis. J Biol Chem 2011;286:11254–64. [PubMed: 21252239]

21. Hill KS, Erdogan E, Khoor A, Walsh MP, Leitges L, Murray NR, Fields AP. Protein Kinase Cα suppresses Kras-mediated lung tumor formation through activation of a p38 MAPK-TGFβ signaling axis. Oncogene 2014;33:2134–44. [PubMed: 23604119]

22. Casado-Medrano V, Barrio-Real L, Wang A, Cooke M, Lopez-Haber C, Kazanietz MG. Distinctive requirement of PKCε in the control of Rho GTPases in epithelial and mesenchymally transformed lung cancer cells. Oncogene 2019;38:5396–412. [PubMed: 30923343]

23. Ivaska J, Bosca L, Parker PJ. PKCepsilon is a permissive link in integrin-dependent IFN-gamma signalling that facilitates JAK phosphorylation of STAT1. Nat Cell Biol 2003;5:363–69. [PubMed: 12640464]

24. Ivaska J, Whelan RD, Watson R, Parker PJ. PKC epsilon controls the traffic of beta1 integrins in motile cells. EMBO J 2002;21:3608–19. [PubMed: 12110574]

25. Dann SG, Golas J, Miranda M, Shi C, Wu J, Jin G, et al. p120 catenin is a key effector of a Ras-PKCepsilon oncogenic signaling axis. Oncogene 2014;33:1385–94. [PubMed: 23542175]

Figure 1. PKCε is required for the formation of Kras-driven lung lesions.
Panel A. Kaplan-Meier analysis was carried out in a set of 425 patients with lung adenocarcinomas. Patients were categorized as "*PRKCE* high" (*red lines*) and "*PRKCE* low" (*blue lines*) according to the median expression of *PRKCE* profile. Databases employed: GEO31210, E-MTAB923 and TCGA-LUAD. *Upper left*, all patients; *upper right*, wild-type KRAS patients; *lower left*, mutant KRAS patients; *lower right*, *PRKCE* expression in wild-type and mutant *KRAS* lung tumors using TCGA-LUAD. *Panel B.* Experimental approach. *Panel C. Left*, representative photomicrographs of H&E stained lungs.

Magnification: 2X. *Right,* number of lesions in lungs from mice sacrificed 32 weeks after Ad-Cre delivery. Results are expressed as mean ± S.E.M. (n=8–11/group). *Panel D.* Kaplan-Meier analysis of mice survival post Ad-Cre delivery (n=8/group, $p < 0.05$).

Figure 2. B[a]P-induced lung tumorigenesis is impaired in PKCɛ KO mice.
A/J PKCɛ$^{+/+}$, PKCɛ$^{+/-}$ and PKCɛ$^{-/-}$ mice (6–8-week old) were treated with B[a]P (1 mg/ml, *i.p.*, once/week for 4 weeks) and sacrificed 20 weeks later. *Panel A.* Experimental approach. *Panel B.* Representative photomicrographs of H&E stained lungs. Magnification: 2X. *Panel C.* Incidence of total lesions, hyperplastic lesions and adenomas. *Panel D.* Analysis of multiplicity of lesions. Results are expressed as mean ± S.E.M. (n=16–25/ group).

A

B

Figure 3. PKCɛ RNAi does not affect signaling of KRAS mutant NSCLC cells.
Panel A. Signaling analysis, 48 h after transfection with PKCɛ siRNA duplexes. *Left*, representative experiment. *Right*, densitometric analysis of 3 independent experiments. Results are expressed as mean ± S.E.M. *Panel B.* H2009 cells were treated with PKC inhibitors GF109203X (3 μM) and Gö6976 (3 μM) for either 1 or 3 h. *Left panel*, representative Western blots with the indicated antibodies. *Right panels*, densitometric analysis of 3 independent experiments. Results were expressed as mean ± S.E.M.

Figure 4. Gene expression analysis in PKCε- and KRAS-depleted NSCLC cells.
H2009 cells were subjected to PKCε RNAi (ε1 or ε3 siRNA duplexes) or KRAS RNAi (K1 or K3 siRNA duplexes), and RNA-Seq analysis for gene expression was performed 48 h after transfection. As controls we used NTC RNAi and parental cells. Three replicates were done for each condition. *Panel A*. Validation of PKCε and KRAS silencing from the RNA-Seq data in individual samples. *Panel B*. Heatmap of 73 deregulated genes (*DEG*) in H2009 cells subjected to PKCε RNAi depletion (*upper panel*) or KRAS RNAi depletion (*lower panel*). The color scale at the bottom of the heatmap is used to represent expression level

(*green*, low expression; *red*, high expression). Fold-change > 2; FDR < 0.01). *Panel C.* Venn diagram of transcripts commonly modulated among PKCε and KRAS silenced H2009 cells. *Panel D.* Top bioprocess enriched in the PKCε and KRAS gene expression signatures. The red dotted line indicates the cut off for statistical significance (p<0.05) (*upper panel*). A comparative analysis of the bioprocesses commonly enriched across the PKCε and KRAS regulated genes was done using the InnateDB resource (*lower panel*).